Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Ashish C. Bhatia MD, FAAD Associate Editor

Jane M. Grant-Kels MD, FAAD Advisory Board

See All Experts

featured

Published in Dermatology

Journal Scan / Research · May 29, 2023

Successful Tapering of Dupilumab in Patients With Atopic Dermatitis With Low Disease Activity

The British Journal of Dermatology

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Adam Friedman MD, FAAD

The British Journal of Dermatology

Successful tapering of dupilumab in atopic dermatitis patients with low disease activity: a large pragmatic daily practice study from the BioDay registry

Br J Dermatol 2023 May 13;[EPub Ahead of Print], LS Spekhorst, CM Boesjes, L Loman, NPA Zuithoff, DS Bakker, E Kamphuis, M Kamsteeg, I Haeck, AJ Oosting, PPM van Lumig, AMT van Lynden-van Nes, RA Tupker, A Flinterman, FM Garritsen, WRH Touwslager, MS de Bruin-Weller, ML Schuttelaar, M de Graaf

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Successful Tapering of Dupilumab in Patients With Atopic Dermatitis With Low Disease Activity

Additional Info

Successful tapering of dupilumab in atopic dermatitis patients with low disease activity: a large pragmatic daily practice study from the BioDay registry

Further Reading

Efficacy of Treatment With Secukinumab in Patients With Hidradenitis Suppurativa

Clinical Features and Treatment Outcomes Among Patients With Primary Cutaneous B-Cell Lymphomas

Clinical Characteristics and Outcomes of DPP-4 Inhibitor–Associated Bullous Pemphigoid

Efficacy and Safety of Tofacitinib vs Azathioprine in Patients With Alopecia Areata and Its Variants

Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Initially Treated With Baricitinib 4 mg

Association Between 5α-Reductase Inhibitor Use for Dermatologic Conditions and the Risk of Breast or Gynecologic Cancers

Safety and Effectiveness of a Targeted Alkali Thermolysis Patch for the Treatment of Patients With Primary Axillary Hyperhidrosis or Excessive Axillary Sweating

Outcomes of Continued Ritlecitinib Treatment Through Week 48 in Patients With Alopecia Areata With or Without Early Target Responses

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

Association Between Treatment With Biologics and Cardiovascular Comorbidities in Patients With Psoriasis

Evaluation and Surgical Management of Pediatric Cutaneous Melanoma, Atypical Spitz Tumors, and Non-Spitz Melanocytic Tumors

Recently Updated